Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app give prostate cancer patients more control?

NCT ID NCT07828951

Knowledge-focused Sponsor: Constantinos Zamboglou Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 18, 2026 · Last updated Sep 18, 2026

Summary

Researchers are studying whether a mobile health app called myAria helps adult prostate cancer patients track symptoms, share health data, and feel more empowered during treatment. Participants use the app to log side effects and well-being, complete questionnaires, and view a nomogram tool with their doctor to discuss treatment plans. The study measures whether the app flags warning signs like pain or infection and whether patients report feeling more knowledgeable and involved in decisions. The trial enrolls 50 patients at the German Oncology Center and German Medical Institute.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a mobile health app called myAria that gives patients personalized health information and a nomogram tool
What this could lead to
If the app works well, it could give doctors a simple way to help prostate cancer patients understand their health and take a more active role in treatment decisions.
What could go wrong
This is a small observational study of 50 people at one center, so the results may not apply broadly. The app's benefits depend on patients using it consistently, and the empowerment questionnaire is new and still being tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study is open to all males aged 18 to 80 years of age with a prostate cancer diagnosis who have not received previous radiotherapy to the pelvis and wish to receive their treatment at GOC/GMI. If they are willing to take part in this research study, they will be invited to download the mobile health application on their phone (also tablets available at the Center for this purpose), complete the eligibility questionnaire, sign the consent form and provide their phone number for account registration with the app and enrollment into the study. The patient study population is via purpose sampling.

Ages

18 to 80 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least 18 and below 80 years of age * Prostate cancer diagnosis * Speak fluent English or Greek * Not had previous radiotherapy to the pelvis * Wishing to receive treatment at the German Oncology Center (GOC) or German Medical Institute (GMI) * Willing to take part in this research study, which lasts up to six months * Sign an informed consent form Exclusion Criteria: * Younger than 18 years or over 80 years of age * Other than prostate cancer diagnosis * Previous radiotherapy to the pelvis * Not wishing to receive treatment at the German Oncology Center (GOC) or German Medical Institute (GMI) * Not willing to take part in this research study * No signed informed consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Empowerment, patient are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Patient Participation prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Empowerment, patient Mobile application Prostate ca

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • German Oncology Center

    Limassol, 4108, Cyprus

More trials for these conditions

Other studies related to the condition(s) this trial covers.